Additionally, the mechanism through which ADORA2A alleviates CCH-induced white matter injury was investigated to identify possible targets that could be used for the clinical treatment of cerebral small vessel disease and thereby improve the quality of life of affected patients. The gene discussed is ADORA2A; the disease is cerebral small vessel disease.